Sparking expectations for an IPO to come, gene therapy specialist Audentes Therapeutics Inc. closed an oversubscribed $65 million series C financing co-led by crossover investors Sofinnova Ventures and Redmile Group, a new investor. Read More
"We've done everything we can to set ourselves up for success," Ralf Schmid, chief operating officer of Nabriva Therapeutics AG, told BioWorld Today, referring to models tested with phase III-ready lefamulin in community-acquired bacterial pneumonia (CABP). Read More
LONDON – The UK's National Institute for Health and Care Excellence (NICE) has opened an Office for Market Access (OMA) to provide advice on what evidence companies should gather during clinical development in order to pass muster in the health technology assessments that follow marketing approvals for new drugs. Read More
DUBLIN – Minoryx Therapeutics SL closed a €19.4 million (US$22.1 million) series A round to take forward a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist in X-linked adrenoleukodystrophy (ALD). Read More
Aclaris Therapeutics Inc., of Malvern, Pa., said it closed its IPO of about 5.8 million shares of common stock priced at $11 per share, including the exercise in full of the underwriters' overallotment option for up to an additional 750,000 shares. Read More
Cara Therapeutics Inc., of Shelton, Conn., earned $2.5 million in milestone payments under its CR-845 development and licensing agreements with Maruishi Pharmaceutical Co. Ltd., of Japan, and Chong Kun Dang Pharmaceutical Corp. (CKD), of South Korea. Read More
Dilaforette AB, of Stockholm, a Karolinska Development AB company, said it enrolled the first patient in a phase II study of polysaccharide drug sevuparin in patients with sickle cell disease (SCD). Read More
